FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366241520> ?p ?o ?g. }

• W4366241520 endingPage "1283" @default.
• W4366241520 startingPage "1283" @default.
• W4366241520 abstract "The Inflation Reduction Act of 2022 authorizes Medicare to negotiate prices of top-selling drugs based on several factors, including therapeutic benefit compared with existing treatment options.To determine the added therapeutic benefit of the 50 top-selling brand-name drugs in Medicare in 2020, as assessed by health technology assessment (HTA) organizations in Canada, France, and Germany.In this cross-sectional study, publicly available therapeutic benefit ratings, US Food and Drug Administration documents, and the Medicare Part B and Part D prescription drug spending dashboards were used to determine the 50 top-selling single-source drugs used in Medicare in 2020 and to assess their added therapeutic benefit ratings through 2021.Ratings from HTA bodies in Canada, France, and Germany were categorized as high (moderate or greater) or low (minor or no) added benefit. Each drug was rated based on its most favorable rating across countries, indications, subpopulations, and dosage forms. We compared the use and prerebate and postrebate (ie, net) Medicare spending between drugs with high vs low added benefit.Forty-nine drugs (98%) received an HTA rating by at least 1 country; 22 of 36 drugs (61%) received a low added benefit rating in Canada, 34 of 47 in France (72%), and 17 of 29 in Germany (59%). Across countries, 27 drugs (55%) had a low added therapeutic rating, accounting for $19.3 billion in annual estimated net spending, or 35% of Medicare net spending on the 50 top-selling single-source drugs and 11% of total Medicare net prescription drug spending in 2020. Compared with those with high added benefit, drugs with a low added therapeutic rating were used by more Medicare beneficiaries (median 387 149 vs 44 869) and had lower net spending per beneficiary (median $992 vs $32 287).Many top-selling Medicare drugs received low added benefit ratings by the national HTA organizations of Canada, France, and Germany. When negotiating prices for these drugs, Medicare should ensure they are not priced higher than reasonable therapeutic alternatives." @default.
• W4366241520 created "2023-04-20" @default.
• W4366241520 creator A5074257304 @default.
• W4366241520 creator A5083543943 @default.
• W4366241520 creator A5086415236 @default.
• W4366241520 date "2023-04-18" @default.
• W4366241520 modified "2023-10-16" @default.
• W4366241520 title "Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare" @default.
• W4366241520 cites W1826923552 @default.
• W4366241520 cites W2002657022 @default.
• W4366241520 cites W2132584445 @default.
• W4366241520 cites W2513403311 @default.
• W4366241520 cites W2596664472 @default.
• W4366241520 cites W2606956625 @default.
• W4366241520 cites W2935300031 @default.
• W4366241520 cites W2986580371 @default.
• W4366241520 cites W2990816998 @default.
• W4366241520 cites W3003763345 @default.
• W4366241520 cites W3027374344 @default.
• W4366241520 cites W3039642681 @default.
• W4366241520 cites W3088810398 @default.
• W4366241520 cites W3090656846 @default.
• W4366241520 cites W3091939515 @default.
• W4366241520 cites W3119503726 @default.
• W4366241520 cites W3134100899 @default.
• W4366241520 cites W3137078259 @default.
• W4366241520 cites W3159396154 @default.
• W4366241520 cites W3170619058 @default.
• W4366241520 cites W3187411614 @default.
• W4366241520 cites W3197690460 @default.
• W4366241520 cites W4226055979 @default.
• W4366241520 cites W4226245778 @default.
• W4366241520 cites W4229036764 @default.
• W4366241520 cites W4248361447 @default.
• W4366241520 cites W4281753215 @default.
• W4366241520 cites W4281869089 @default.
• W4366241520 cites W4310052022 @default.
• W4366241520 cites W4318240943 @default.
• W4366241520 doi "https://doi.org/10.1001/jama.2023.4034" @default.
• W4366241520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37071095" @default.
• W4366241520 hasPublicationYear "2023" @default.
• W4366241520 type Work @default.
• W4366241520 citedByCount "8" @default.
• W4366241520 countsByYear W43662415202023 @default.
• W4366241520 crossrefType "journal-article" @default.
• W4366241520 hasAuthorship W4366241520A5074257304 @default.
• W4366241520 hasAuthorship W4366241520A5083543943 @default.
• W4366241520 hasAuthorship W4366241520A5086415236 @default.
• W4366241520 hasConcept C100001284 @default.
• W4366241520 hasConcept C160735492 @default.
• W4366241520 hasConcept C162324750 @default.
• W4366241520 hasConcept C2426938 @default.
• W4366241520 hasConcept C2776291444 @default.
• W4366241520 hasConcept C2778829437 @default.
• W4366241520 hasConcept C2778858636 @default.
• W4366241520 hasConcept C2780035454 @default.
• W4366241520 hasConcept C2910862244 @default.
• W4366241520 hasConcept C3018890749 @default.
• W4366241520 hasConcept C50522688 @default.
• W4366241520 hasConcept C71924100 @default.
• W4366241520 hasConcept C98274493 @default.
• W4366241520 hasConceptScore W4366241520C100001284 @default.
• W4366241520 hasConceptScore W4366241520C160735492 @default.
• W4366241520 hasConceptScore W4366241520C162324750 @default.
• W4366241520 hasConceptScore W4366241520C2426938 @default.
• W4366241520 hasConceptScore W4366241520C2776291444 @default.
• W4366241520 hasConceptScore W4366241520C2778829437 @default.
• W4366241520 hasConceptScore W4366241520C2778858636 @default.
• W4366241520 hasConceptScore W4366241520C2780035454 @default.
• W4366241520 hasConceptScore W4366241520C2910862244 @default.
• W4366241520 hasConceptScore W4366241520C3018890749 @default.
• W4366241520 hasConceptScore W4366241520C50522688 @default.
• W4366241520 hasConceptScore W4366241520C71924100 @default.
• W4366241520 hasConceptScore W4366241520C98274493 @default.
• W4366241520 hasIssue "15" @default.
• W4366241520 hasLocation W43662415201 @default.
• W4366241520 hasLocation W43662415202 @default.
• W4366241520 hasOpenAccess W4366241520 @default.
• W4366241520 hasPrimaryLocation W43662415201 @default.
• W4366241520 hasRelatedWork W2056852023 @default.
• W4366241520 hasRelatedWork W2165314690 @default.
• W4366241520 hasRelatedWork W2226648823 @default.
• W4366241520 hasRelatedWork W2278327597 @default.
• W4366241520 hasRelatedWork W2618458756 @default.
• W4366241520 hasRelatedWork W2910374806 @default.
• W4366241520 hasRelatedWork W3123494875 @default.
• W4366241520 hasRelatedWork W745843498 @default.
• W4366241520 hasRelatedWork W2588603958 @default.
• W4366241520 hasRelatedWork W2910357933 @default.
• W4366241520 hasVolume "329" @default.
• W4366241520 isParatext "false" @default.
• W4366241520 isRetracted "false" @default.
• W4366241520 workType "article" @default.